The recent introduction of the echinocandins to clinical practice represents a welcome addition to the antifungal armamentarium. This new class of drugs with their novel mode of antifungal action have several advantages over existing agents. They are most active against the principal invasive fungal pathogens Candida and Aspergillus spp, they have low toxicity for patients, and they have potential value in combination therapy.
|Journal||Journal of Invasive Fungal Infections|
|Publication status||Published - Jan 2007|